Condition (MeSH)
Cystadenoma, Serous
ClinicalTrials.gov lists 6 trials for Cystadenoma, Serous or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Cystadenoma, Serous itself; the rest are tagged with a narrower condition beneath it.
When did Cystadenoma, Serous trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cystadenoma, Serous trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 3 |
| Observational | 3 |
How many Cystadenoma, Serous trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 1 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Cystadenoma, Serous? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors. | Journal of ovarian research | 2019 | Yes |
| Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions (with video). | Gastrointestinal endoscopy | 2018 | Yes |
| Moray micro forceps biopsy improves the diagnosis of specific pancreatic cysts. | Cancer cytopathology | 2018 | Yes |
| Needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cystic lesions: an international external interobserver and intraobserver study (with videos). | Gastrointestinal endoscopy | 2017 | Yes |
| Does preoperative neutrophil to lymphocyte or platelet to lymphocyte ratios have a role in predicting borderline ovarian tumors? | Journal of ovarian research | 2016 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.